David Fudman, M.D. Director, Inflammatory Bowel Disease Clinics | Quality Officer, Division of Digestive and Liver Diseases Assistant Professor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography David I. Fudman, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Digestive and Liver Diseases. He specializes in the treatment of inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. Dr. Fudman holds a bachelor's degree in biology and politics from Brandeis University in Waltham, Massachusetts. He earned his medical degree at UT Southwestern and completed a residency in internal medicine at New York-Presbyterian/Columbia University Medical Center. He then obtained training in treating inflammatory bowel disease through a fellowship in gastroenterology and hepatology at Beth Israel-Deaconess Medical Center/Harvard Medical School in Boston. Board certified in internal medicine and gastroenterology, Dr. Fudman joined the UT Southwestern faculty in 2018. His research interests include quality improvement, Crohn's disease and ulcerative colitis. Dr. Fudman is an active member of several professional organizations, including the American Gastroenterological Association, American College of Gastroenterology, and the Crohn's and Colitis Foundation. Education Medical School UT Southwestern Medical School (2011) Residency Columbia University Medical Center/New York Presbyterian Hospital (2014), Internal Medicine Fellowship Beth Isreal Deaconess Medical Center (2018), Gastroenterology Research Interest Inflammatory bowel disease Quality improvement Publications Featured Publications Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review. Fudman DI, Perez-Reyes AE, Niccum BA, Melmed GY, Khalili H, Clin Gastroenterol Hepatol 2021 Sep Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease. Yin J, El-Najjar Y, Cordova N, Touma MJ, Nguyen N, Boktor M, Burstein E, Fudman DI, Inflamm Bowel Dis 2024 May Isolated gastrointestinal histoplasmosis with a negative urine antigen test mimicking ulcerative colitis flare: a case report. Yin J, Balachandar N, Karamchandani D, Vemulapalli R, Fudman DI, Gastroenterol Rep (Oxf) 2024 12 goae013 Monitoring Postoperative Crohn's Disease-Closing the Gap. Fudman DI, Dig Dis Sci 2023 Sep 68 9 3485-3487 Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Holmer AK, Luo J, Russ KB, Park S, Yang JY, Ertem F, Dueker J, Nguyen V, Hong S, Zenger C, Axelrad JE, Sofia A, Petrov JC, Al-Bawardy B, Fudman DI, Llano E, Dailey J, Jangi S, Khakoo N, Damas OM, Barnes EL, Scott FI, Ungaro RC, Singh S, Clin Gastroenterol Hepatol 2023 Jun 21 6 1598-1606.e5 Automated Clinical Pathway Utilizing Custom Risk Stratification Identifies Substantial Rates of Overdue Follow-up Among Patients With Inflammatory Bowel Disease and Facilitates Population Health Interventions. Schroeder MK, Tan SA, Touma MJ, Basit M, Fudman DI, Inflamm Bowel Dis 2023 Mar Improved Healthcare Access Reduces Requirements for Surgery in Indigent IBD Patients Using Biologic Therapy: A 'Safety-Net' Hospital Experience. Gu P, Clifford E, Gilman A, Chang C, Moss E, Fudman DI, Kilgore P, Cvek U, Trutschl M, Alexander JS, Burstein E, Boktor M, Pathophysiology 2022 Jul 29 3 383-393 Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Alayo QA, Fenster M, Altayar O, Glassner KL, Llano E, Clark-Snustad K, Patel A, Kwapisz L, Yarur AJ, Cohen BL, Ciorba MA, Thomas D, Lee SD, Loftus EV, Fudman DI, Abraham BP, Colombel JF, Deepak P, Crohns Colitis 360 2022 Jan 4 1 otac002 Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. Pozdnyakova V, Botwin GJ, Sobhani K, Prostko J, Braun J, Mcgovern DPB, Melmed GY, Appel K, Banty A, Feldman E, Ha C, Kumar R, Lee S, Rabizadeh S, Stein T, Syal G, Targan S, Vasiliauskas E, Ziring D, Debbas P, Hampton M, Mengesha E, Stewart JL, Frias EC, Cheng S, Ebinger J, Figueiredo JC, Boland B, Charabaty A, Chiorean M, Cohen E, Flynn A, Valentine J, Fudman D, Horizon A, Hou J, Hwang C, Lazarev M, Lum D, Fausel R, Reddy S, Mattar M, Metwally M, Ostrov A, Parekh N, Raffals L, Sheibani S, Siegel C, Wolf D, Younes Z, Gastroenterology 2021 12 161 6 2041-2043.e1 Prevalence of Forceps Polypectomy of Non-Diminutive Polyps is Substantial but Modifiable. Fudman DI, Singal AG, Cooper MG, Lee M, Murphy CC, Clin Gastroenterol Hepatol 2021 Nov Results 1-10 of 22 1 2 3 Next Last Books Featured Books Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease. In Treatment of Inflammatory Bowel Disease with Biologics Fudman DI, Flier SN (2017). Springer Quality in Gastroenterology. In Quality in Gastroenterology: A Concise Guide to Establishing High Value Clinical Care Fudman DI, Zuberi S, Feuerstein JD. (2024). Springer Honors & Awards Physician of the YearCrohn's and Colitis Foundation, North Texas Chapter (2024) Fellowship Award for Quality ImprovementBeth Israel Deaconess Medical Center (2017) Presidential Merit ScholarshipBrandeis University (2003) Professional Associations/Affiliations American College of Gastroenterology American Gastroenterological Association Crohn's & Colitis Foundation
